Genetic testing is underused, even in families with a history of certain cancers, reports [email protected]. A team of French researchers examined about 240,000 patient records from cancer centers in France. While the researchers found that BRCA1 and BRCA2 gene testing about tripled between 2003 and 2011, testing rates for other cancer-predisposing genes remained low.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.